$11.78
15.50% yesterday
Nasdaq, Jun 13, 10:15 pm CET
ISIN
US14070B1017
Symbol
CAPR
Sector
Industry

Capricor Therapeutics, Inc. Stock price

$11.78
+4.48 61.37% 1M
-1.48 11.16% 6M
-2.02 14.64% YTD
+6.49 122.68% 1Y
+7.08 150.64% 5Y
-40.12 77.30% 10Y
+5.28 81.23% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-2.16 15.50%
ISIN
US14070B1017
Symbol
CAPR
Sector
Industry

Key metrics

Market capitalization $637.17m
Enterprise Value $495.77m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 28.56
P/S ratio (TTM) P/S ratio 36.70
P/B ratio (TTM) P/B ratio 4.99
Revenue growth (TTM) Revenue growth -35.96%
Revenue (TTM) Revenue $17.36m
EBIT (operating result TTM) EBIT $-57.28m
Free Cash Flow (TTM) Free Cash Flow $-47.18m
Cash position $144.78m
EPS (TTM) EPS $-1.20
P/E forward 43.56
P/S forward 5.38
EV/Sales forward 4.19
Short interest 27.58%
Show more

Is Capricor Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Capricor Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Capricor Therapeutics, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Capricor Therapeutics, Inc. forecast:

Buy
100%

Financial data from Capricor Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
17 17
36% 36%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 17 17
25% 25%
96%
- Research and Development Expense 58 58
44% 44%
332%
-57 -57
128% 128%
-328%
- Depreciation and Amortization 0.41 0.41
65% 65%
2%
EBIT (Operating Income) EBIT -57 -57
119% 119%
-330%
Net Profit -55 -55
126% 126%
-317%

In millions USD.

Don't miss a Thing! We will send you all news about Capricor Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Capricor Therapeutics, Inc. Stock News

Positive
Seeking Alpha
2 days ago
I am downgrading Capricor Therapeutics, Inc. stock from Strong Buy to Hold due to FDA Form 483 risks from a Pre-License Inspection of its manufacturing facility. While deramiocel's clinical data for DMD Cardiomyopathy is strong, the unresolved FDA inspection findings create significant regulatory uncertainty for CAPR. The timing of the FDA Advisory Committee meeting and PDUFA date introduces ad...
Neutral
GlobeNewsWire
3 days ago
SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the successful completion of the U.S. Food and Drug Administration's (FDA) Pre-License Inspection (PLI) of its San Diego manufacturing facility for Deramiocel, the Company's le...
Positive
Seeking Alpha
22 days ago
Capricor Therapeutics basically has two platforms: Deramiocel CDC therapy and the StealthX exosome platform. However, its flagship candidate is undoubtedly Deramiocel, which has so far secured a PDUFA date for August 31, 2025. Deramiocel's Phase II and extension trials in over 250 DMD patients suggest this candidate has very favorable safety and efficacy for cardiomyopathy DMD.
More Capricor Therapeutics, Inc. News

Company Profile

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

Head office United States
CEO Linda Marbán
Employees 160
Founded 1996
Website capricor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today